Insmed, Inc. $INSM Position Reduced by Long Focus Capital Management LLC

Key Points

• Long Focus Capital Management LLC sold 20,000 shares of Insmed, reducing its stake by 3.1%, and now holds 630,800 shares valued at approximately $48.12 million.
• Insmed reported a loss of ($1.70) earnings per share for the last quarter, missing analysts' expectations, though its revenue increased by 18.9% year-over-year to $107.42 million.
• Analysts remain optimistic, with multiple firms raising their price targets for Insmed's shares, now averaging a consensus price target of $132.57.

Long Focus Capital Management LLC lessened its stake in Insmed, Inc. (NASDAQ:INSM - Free Report) by 3.1% in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 630,800 shares of the biopharmaceutical company's stock after selling 20,000 shares during the period. Insmed comprises about 1.6% of Long Focus Capital Management LLC's investment portfolio, making the stock its 13th largest position. Long Focus Capital Management LLC owned approximately 0.35% of Insmed worth $48,124,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds also recently modified their holdings of INSM. Nuveen LLC acquired a new stake in shares of Insmed during the first quarter worth $88,351,000. Brown Advisory Inc. acquired a new stake in shares of Insmed during the fourth quarter worth $45,773,000. Duquesne Family Office LLC raised its holdings in shares of Insmed by 2,867.4% during the fourth quarter. Duquesne Family Office LLC now owns 593,470 shares of the biopharmaceutical company's stock worth $40,973,000 after purchasing an additional 573,470 shares during the period. 1832 Asset Management L.P. acquired a new stake in shares of Insmed during the first quarter worth $37,214,000. Finally, Wellington Management Group LLP raised its holdings in shares of Insmed by 62.5% during the first quarter. Wellington Management Group LLP now owns 1,222,627 shares of the biopharmaceutical company's stock worth $93,274,000 after purchasing an additional 470,401 shares during the period.

Insmed Price Performance

INSM traded down $1.80 on Wednesday, reaching $143.50. The company had a trading volume of 2,493,986 shares, compared to its average volume of 2,809,975. The company has a fifty day moving average of $112.13 and a 200-day moving average of $88.41. The company has a market capitalization of $30.33 billion, a P/E ratio of -25.13 and a beta of 0.97. The company has a current ratio of 6.68, a quick ratio of 6.33 and a debt-to-equity ratio of 0.45. Insmed, Inc. has a one year low of $60.40 and a one year high of $146.84.

Insmed (NASDAQ:INSM - Get Free Report) last announced its earnings results on Thursday, August 7th. The biopharmaceutical company reported ($1.70) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.30) by ($0.40). The company had revenue of $107.42 million during the quarter, compared to the consensus estimate of $104.06 million. Insmed had a negative net margin of 259.82% and a negative return on equity of 195.37%. The business's quarterly revenue was up 18.9% on a year-over-year basis. During the same quarter in the prior year, the company earned ($1.94) EPS. Insmed has set its FY 2025 guidance at EPS. As a group, equities research analysts anticipate that Insmed, Inc. will post -4.56 earnings per share for the current year.

Insider Transactions at Insmed

In other news, insider Orlov S. Nicole Schaeffer sold 99,172 shares of the firm's stock in a transaction dated Wednesday, June 11th. The shares were sold at an average price of $93.42, for a total transaction of $9,264,648.24. Following the completion of the transaction, the insider owned 89,407 shares in the company, valued at approximately $8,352,401.94. This trade represents a 52.59% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, CFO Sara Bonstein sold 58,400 shares of the company's stock in a transaction dated Monday, July 21st. The shares were sold at an average price of $102.67, for a total transaction of $5,995,928.00. Following the sale, the chief financial officer directly owned 73,505 shares of the company's stock, valued at $7,546,758.35. This represents a 44.27% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 512,927 shares of company stock worth $51,227,401 over the last ninety days. Insiders own 3.00% of the company's stock.

Analyst Ratings Changes

A number of analysts have weighed in on INSM shares. Royal Bank Of Canada increased their target price on shares of Insmed from $108.00 to $120.00 and gave the stock an "outperform" rating in a report on Friday, August 8th. Truist Financial increased their target price on shares of Insmed from $126.00 to $139.00 and gave the stock a "buy" rating in a report on Thursday, August 14th. Wells Fargo & Company increased their price objective on shares of Insmed from $140.00 to $171.00 and gave the stock an "overweight" rating in a report on Wednesday. William Blair initiated coverage on shares of Insmed in a report on Wednesday, August 20th. They issued an "outperform" rating on the stock. Finally, Morgan Stanley increased their price objective on shares of Insmed from $126.00 to $144.00 and gave the stock an "equal weight" rating in a report on Thursday, August 21st. Sixteen investment analysts have rated the stock with a Buy rating and one has issued a Hold rating to the stock. Based on data from MarketBeat.com, Insmed currently has an average rating of "Moderate Buy" and an average target price of $134.79.

Insmed Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.